CAS No: 120511-73-1
Appearance: white powder.
The drug is appropriately used when using substantial amounts of aromatizing steroids, or when one is prone to gynecomastia and using moderate amounts of such steroids. Arimidex does not have the side effects of aminoglutethimide (Cytadren) and can achieve a high degree of estrogen blockade, much moreso than Cytadren. It is possible to reduce estrogen too much with Arimidex, and for this reason blood tests, or less preferably salivary tests, should be taken after the first week of use to determine if the dosing is correct.
The trial suggested that anastrozole is the preferred medical therapy for postmenopausal women with localized estrogen receptor (ER) positive breast cancer.
|Description||White crystalline powder||Complies|
|Conform with standard IR
Conform with standard HPLC
|Solubility||Freely soluble in methanol,acetone,ethanol and tetrahydrofuran.And very soluble in acetonitrile||Complies|
|Total Unspecified Impurity||max. 0.2%||0.08%|
|Individual unspecified impurlty||max. 0.1%||0.05%|
|Related compound B||max. 0.2%||0.07%|
|Related compound C||max. 0.2%||0.04%|
|Related compound D||max. 0.1%||0.05%|
|Related compound E||max. 0.1%||0.06%|
|Limit of cyclohexane||max. 0.08%||ND|
|Limit of ethylacetate||max. 0.1%||0.07%|
|Residue on ignition||max. 0.1%||0.07%|
|Storage||Cool and dry|
|Conclusion||It complies to USP32 .|